Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
OFS Capital Corp is an asset management business based in the US. OFS Capital shares (OFS) are listed on the NASDAQ and all prices are listed in US Dollars. OFS Capital employs 50 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Active traders
| Latest market close | $10.02 |
|---|---|
| 52-week range | $7.99 - $13.14 |
| 50-day moving average | $11.88 |
| 200-day moving average | $11.22 |
| Wall St. target price | $12.75 |
| PE ratio | 2.2791 |
| Dividend yield | $0.99 (11.19%) |
| Earnings per share (TTM) | $4.55 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $10.02 from 2022-07-05
| 1 week (2022-06-29) | -2.15% |
|---|---|
| 1 month (2022-06-07) | -21.90% |
| 3 months (2022-04-07) | -20.35% |
| 6 months (2022-01-07) | -7.48% |
| 1 year (2021-07-07) | 3.09% |
|---|---|
| 2 years (2020-07-07) | 113.19% |
| 3 years (2019-07-05) | 12.26 |
| 5 years (2017-07-06) | 14.03 |
Valuing OFS Capital stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of OFS Capital's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
OFS Capital's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, OFS Capital shares trade at around 2x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
OFS Capital's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6667. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into OFS Capital's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
OFS Capital's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $30.5 million.
The EBITDA is a measure of a OFS Capital's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $48.2 million |
|---|---|
| Operating margin TTM | 62.67% |
| Gross profit TTM | $47.8 million |
| Return on assets TTM | 3.49% |
| Return on equity TTM | 33.1% |
| Profit margin | 126.62% |
| Book value | $15.53 |
| Market capitalisation | $139.2 million |
TTM: trailing 12 months
Dividend payout ratio: 102.91% of net profits
Recently OFS Capital has paid out, on average, around 102.91% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 11.19% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), OFS Capital shareholders could enjoy a 11.19% return on their shares, in the form of dividend payments. In OFS Capital's case, that would currently equate to about $0.99 per share.
OFS Capital's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
OFS Capital's most recent dividend payout was on 29 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 21 June 2022 (the "ex-dividend date").
Over the last 12 months, OFS Capital's shares have ranged in value from as little as $7.9897 up to $13.1396. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OFS Capital's is 1.8035. This would suggest that OFS Capital's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
OFS Capital Corporation is a business development company specializing in direct and fund investments as well as add-on acquisitions. It provides flexible capital solutions primarily through debt capital and to a lesser extent, minority equity investments serving the needs of U. S. -based middle-market companies across a broad array of industries. It does not invest in operational turnarounds or start-up businesses. For direct, it specializes in debt and structured equity investments, recapitalizations and refinancing, management and leveraged buyouts, acquisition financings, shareholder liquidity events, growth capital, independent sponsor transactions, ESOPs, and minority investments in the lower middle market companies. It invests in the aerospace and defense, business services, consumer products and services, food and beverage, health care services, specialty chemicals, transportation and logistics, value added distribution, franchising, and industrial and niche manufacturing sectors.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.